Prakash Mistry

4.3k citations

56 papers · 3.5k indexed · h-index 31

Impact in

Oncology top 1%
- Drug Transport and Resistance Mechanisms
- Metal complexes synthesis and properties
Toxicology top 1%

Papers in

Toxicology 6
- Bioactive Compounds and Antitumor Agents 6
Oncology 26
- Drug Transport and Resistance Mechanisms 14
- Metal complexes synthesis and properties 10

Co-authors: Peter Charlton G Abel Richard Callaghan Catherine Martin G. Berridge Kenneth R. Harrap Barry A. Murrer Lloyd R. Kelland
Journals: Cancer Chemotherapy and Pharmacology (7 papers)British Journal of Cancer (6 papers)Anti-Cancer Drugs (4 papers)Journal of Medicinal Chemistry (3 papers)Journal of Pharmacology and Experimental Therapeutics (2 papers)
Partner nations: United Kingdom United States New Zealand

In The Last Decade

Prakash Mistry

55 papers receiving 3.4k citations

Peers

Countries citing papers authored by Prakash Mistry

Since Specialization

Citations

This map shows the geographic impact of Prakash Mistry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Prakash Mistry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Prakash Mistry more than expected).

Fields of papers citing papers by Prakash Mistry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Prakash Mistry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Prakash Mistry. The network helps show where Prakash Mistry may publish in the future.

Co-authors

The 25 scholars most cited alongside Prakash Mistry, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Prakash Mistry Line = papers co-authored together Prakash Mistry links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	H4 Histamine Receptors Mediate Cell Cycle Arrest in Growth Factor-Induced Murine and Human Hematopoietic Progenitor Cells PLoS ONE ·Anne France Petit-Bertron, François Machavoine, Marie Paule Defresne, Michel Gillard, Pierre Chatelain, Prakash Mistry, Elke Schneider, Michel Dy	2009	30
2	Effect of phenazine compounds XR11576 and XR5944 on DNA topoisomerases Cancer Chemotherapy and Pharmacology ·Andrew G. Jobson, Elaine Willmore, Michael J. Tilby, Prakash Mistry, Peter Charlton, Caroline A. Austin	2008	14
3	4-(1,3-Thiazol-2-yl)morpholine derivatives as inhibitors of phosphoinositide 3-kinase Bioorganic & Medicinal Chemistry Letters ·Rikki Alexander, Ahrani Balasundaram, Mark Batchelor, Daniel C. Brookings, Karen Crépy, Tom Crabbe, Marie-France Deltent, Frank Driessens, Andrew B. Gill, S. Welsh Harris, Gillian Hutchinson, Claire Kulisa, Mark Merriman, Prakash Mistry, Ted A.H. Parton, James M. A. Turner, Ian Whitcombe, S. Kirk Wright	2008	35
4	Mode of action of the novel phenazine anticancer agents XR11576 and XR5944 Anti-Cancer Drugs ·Louisa J. Lewis, Prakash Mistry, Peter Charlton, Hilary Thomas, Helen M. Coley	2006	17
5	In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II Anti-Cancer Drugs ·Prakash Mistry, Alistair Stewart, Wendy Dangerfield, Mark Baker, Chris Liddle, Douglas Bootle, Barbara Kofler, Deanne Laurie, William A. Denny, Bruce C. Baguley, Peter Charlton	2002	50
6	Structure–activity relationships for analogues of the phenazine-based dual topoisomerase I/II inhibitor XR11576 Bioorganic & Medicinal Chemistry Letters ·Shouming Wang, Warren Miller, John Milton, Nigel Vicker, Alistair Stewart, Peter Charlton, Prakash Mistry, David Hardick, William A. Denny	2002	49
7	Communication between Multiple Drug Binding Sites on P-glycoprotein Molecular Pharmacology ·Catherine Martin, G. Berridge, Christopher F. Higgins, Prakash Mistry, Peter Charlton, Richard Callaghan	2000	345
8	In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance British Journal of Cancer ·Prakash Mistry, Jane A. Plumb, Sue Eccles, Sue‐Ann Watson, IL Dale, Hamish Ryder, G. Box, Peter Charlton, David J. Templeton, P Bevan	1999	17
9	Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative British Journal of Cancer ·IL Dale, W Tuffley, Richard Callaghan, J. A. Holmes, Karen H. Martin, M Luscombe, Prakash Mistry, Hamish Ryder, Alistair Stewart, Peter Charlton, PR Twentyman, P Bevan	1998	43
10	Biotransformation of the platinum drug JM216 following oral administration to cancer patients Cancer Chemotherapy and Pharmacology ·Florence I. Raynaud, Prakash Mistry, A. Donaghue, Grace K. Poon, Lloyd R. Kèlland, C. F. J. Barnard, Barry A. Murrer, Kenneth R. Harrap	1996	103
11	Metabolic studies of an orally active platinum anticancer drug by liquid chromatography-electrospray ionization mass spectrometry Journal of Chromatography A ·Grace K. Poon, Florence I. Raynaud, Prakash Mistry, D.E. Odell, Lloyd R. Kèlland, Kenneth R. Harrap, C. F. J. Barnard, Barry A. Murrer	1995	44
12	A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration Cancer Chemotherapy and Pharmacology ·Mark J. McKeage, Prakash Mistry, Janet Ward, Frances Boxall, Swee Y. Loh, Ciaran F. O’Neill, Peter Ellis, Lloyd R. Kèlland, Sarah E. Morgan, Barry A. Murrer, P. Santabárbara, Kenneth R. Harrap, Ian Judson	1995	84
13	Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and-resistant human ovarian carcinoma cell lines by amphotericin B Cancer Chemotherapy and Pharmacology ·Swee Y. Sharp, Prakash Mistry, Melanie Valenti, Alex P. Bryant, Lloyd R. Kèlland	1994	21
14	Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian‐carcinoma cell lines International Journal of Cancer ·Prakash Mistry, Swee Y. Loh, Lloyd R. Kèlland, Ken R. Harrap	1993	32
15	Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes British Journal of Cancer ·Swee Y. Loh, Prakash Mistry, LR Kelland, G Abel, Kenneth R. Harrap	1992	145
16	The effects of cisplatin on the concentration of protein thiols and glutathione in the rat kidney Cancer Chemotherapy and Pharmacology ·Prakash Mistry, Y. Merazga, D. J. Spargo, Patrick A. Riley, D. C. H. McBrien	1991	49
17	Historical aspects of glutathione and cancer chemotherapy Pharmacology & Therapeutics ·Prakash Mistry, K.R. Harrap	1991	34
18	The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines British Journal of Cancer ·Prakash Mistry, LR Kelland, G Abel, S Sidhar, KR Harrap	1991	233
19	Intracellular metabolites of cisplatin in the rat kidney Cancer Chemotherapy and Pharmacology ·Prakash Mistry, C. Lee, D. C. H. McBrien	1989	55
20	Studies on the binding site of the cadmium-binding protein (CdBP) from the american oyster (Crassostrea virginica) Marine Environmental Research ·Bruce A. Fowler, Carol Czop, David Elliott, Prakash Mistry, Colin F. Chignell	1984	6

About Prakash Mistry

Prakash Mistry is a scholar working on Toxicology, Oncology, Pathology and Forensic Medicine, Biochemistry and Physiology, having authored 56 papers that have together received 3.5k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (19 papers), Drug Transport and Resistance Mechanisms (14 papers), Metal complexes synthesis and properties (10 papers), Chemotherapy-induced organ toxicity mitigation (9 papers), Bioactive Compounds and Antitumor Agents (6 papers), DNA Repair Mechanisms (5 papers), Pharmacological Effects and Toxicity Studies (4 papers) and Glutathione Transferases and Polymorphisms (4 papers). The work is most often cited by research in Oncology (2.2k citations), Toxicology (155 citations), Organic Chemistry (787 citations), Pediatrics, Perinatology and Child Health (523 citations) and Molecular Biology (1.5k citations). Prakash Mistry has collaborated with scholars based in United Kingdom, United States and New Zealand. Frequent co-authors include Peter Charlton, G Abel, Richard Callaghan, Catherine Martin, G. Berridge, Kenneth R. Harrap, Barry A. Murrer, Lloyd R. Kelland, Wendy Dangerfield and Alistair Stewart. Their work appears in journals such as Cancer Chemotherapy and Pharmacology, British Journal of Cancer, Anti-Cancer Drugs, Journal of Medicinal Chemistry and Journal of Pharmacology and Experimental Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact